Journal article icon

Journal article

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

Abstract:

OBJECTIVES: Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS). Azacitidine, first-line treatment for the majority of patients with higher-risk MDS, is associated with aggravated thrombocytopenia during the first cycles. Eltrombopag is a novel thrombopoietin receptor agonist, which also has been shown to inhibit proliferation of leukaemia cell lines in vitro. This phase I clinical trial was designed to explore the safety and tolerabil...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1111/ejh.12383

Authors


Expand authors...
Journal:
European journal of haematology
Volume:
93
Issue:
5
Pages:
439-445
Publication date:
2014-11-05
DOI:
EISSN:
1600-0609
ISSN:
0902-4441
URN:
uuid:14f0740f-41fc-417d-aa2a-5bfc1e2d5b95
Source identifiers:
471953
Local pid:
pubs:471953

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP